Wesper

Better sleep—for good. Meet the sleep improvement platform that takes care of your sleep health from

08/20/2025

AHI isn’t the full story.

A pulse oximeter alone misses the nuances of sleep health. In our interview with Dr. Atul Malhotra, we explore why real insight comes from looking at the whole patient — from snoring to cardiovascular strain and beyond.

Discover the full interview here:
https://wesper.co/blogs/wesper-journal/rethinking-sleep-apnea-dr-atul-malhotra-on-longitudinal-monitoring-central-apnea-and-the-future-of-glp-1-therapy

08/19/2025

Wake up to Hypoxic Burden 🫁

Join us on Sept 3 at 12PM EST for a special CEC webinar featuring Chelsea Rohrscheib.
Discover why hypoxic burden is redefining sleep diagnostics—and what every provider should know.

👉 Reserve your spot now!
https://wesper.co/pages/webinars

08/18/2025

✨ More channels don’t always mean better results—unless they improve reliability.

When Dr. Atul Malhotra evaluates a home sleep apnea test, he looks first at its diagnostic sensitivity and specificity, then at how many physiological channels it records.

The right HSAT isn’t about bulk data—it’s about the right data, measured precisely, to drive confident clinical decisions.

➡️ Discover the full conversation:
https://wesper.co/blogs/wesper-journal/rethinking-sleep-apnea-dr-atul-malhotra-on-longitudinal-monitoring-central-apnea-and-the-future-of-glp-1-therapy

08/15/2025

ℹ One night can miss the mark.

Up to 20% of moderate OSA cases—especially in women and REM-predominant patients—are misdiagnosed with single-night testing.

In our interview, Dr. Atul Malhotra explains how multi-night, airflow-based monitoring reveals true OSA severity, tracks hypoxic burden, and detects central apnea with unmatched accuracy.

→ Discover the full conversation here:
https://wesper.co/blogs/wesper-journal/rethinking-sleep-apnea-dr-atul-malhotra-on-longitudinal-monitoring-central-apnea-and-the-future-of-glp-1-therapy

08/14/2025

CPAP is just a step—Wesper can help you see the whole journey.

In our conversation with Dr. Atul Malhotra, we explore how longitudinal testing can reveal the real impact of therapy, guide adjustments, and ensure lasting results.

Discover the full interview now:
https://wesper.co/blogs/wesper-journal/rethinking-sleep-apnea-dr-atul-malhotra-on-longitudinal-monitoring-central-apnea-and-the-future-of-glp-1-therapy

08/13/2025

📰 Did you know Wesper has its own newsletter?

Wesper Weekly brings you the latest in sleep science, clinical breakthroughs, and expert insights—straight to your inbox. Stay informed. Stay ahead.

→ Visit Wesper.co to sign up now!
"

08/12/2025

BMI often decides who gets GLP-1 therapy—but it’s only part of the story.

Research shows these medications can improve sleep-disordered breathing through mechanisms beyond weight loss—enhancing airway stability, ventilatory control, and oxygenation before the scale even moves.

Wesper looks deeper, tracking real physiological changes over time—not just a number.
Watch the full interview with Dr. Atul Malhotra here:
https://wesper.co/blogs/wesper-journal/rethinking-sleep-apnea-dr-atul-malhotra-on-longitudinal-monitoring-central-apnea-and-the-future-of-glp-1-therapy

08/11/2025

Sleep medicine is shifting—fast. Dr. Atul Malhotra shares why one-night studies miss the mark, why hypoxic burden matters most, and how GLP-1s like tirzepatide are changing apnea care. The future? Longitudinal, bias-free, airflow-based monitoring.

Discover more in the Wesper journal here:
https://wesper.co/blogs/wesper-journal/rethinking-sleep-apnea-dr-atul-malhotra-on-longitudinal-monitoring-central-apnea-and-the-future-of-glp-1-therapy

08/08/2025

Emerging data suggests that medications like GLP-1s may impact sleep-disordered breathing through mechanisms beyond weight reduction—offering a new lens on how we understand and treat OSA.

The future of sleep medicine is deeper than the scale. Discover our conversation with Dr. Atul Malhotra where we discuss medicine's effect on airway patency, ventilatory control, and arousal thresholds here: https://buff.ly/7Lj9I17

08/07/2025

The future of sleep medicine isn’t just about weight loss.
GLP-1s are revealing deeper mechanisms at play—shifting how we think about airway health, arousal thresholds, and the treatment of OSA.

We sat down with Dr. Atul Malhotra to unpack what this means for clinicians, patients, and the evolving field of sleep medicine.

📖 Read or watch the full conversation now:
https://wesper.co/blogs/wesper-journal/rethinking-sleep-apnea-dr-atul-malhotra-on-longitudinal-monitoring-central-apnea-and-the-future-of-glp-1-therapy

08/06/2025

Medications can change more than just symptoms—they can reshape sleep itself.

From altering hypoxic burden to disrupting sleep architecture, medications (especially GLP-1s, sedatives, and antidepressants) can mask or exacerbate sleep-disordered breathing.

With Wesper’s longitudinal data, providers can track how therapeutic changes impact real-world sleep—night over night. It’s the clarity you can’t get from a single-night study.

Curious? Discover how Wesper works at wesper.co

08/05/2025

What if the future of sleep apnea treatment isn’t just weight loss?

GLP-1s and emerging drugs like AD109 are reframing how we think about OSA—showing improvements in oxygenation and airway control even before weight is lost.

This powerful shift in sleep medicine demands smarter tools—ones that go beyond the single-night snapshot. That’s where Wesper comes in. Our longitudinal platform tracks real-world changes across multiple nights, helping providers measure the true impact of modern therapies.

Read more now in the Wesper Journal.

Address

New York, NY

Telephone

+15754482824

Website

http://wesper.co/

Alerts

Be the first to know and let us send you an email when Wesper posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Wesper: